<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491243</url>
  </required_header>
  <id_info>
    <org_study_id>652/2011/D</org_study_id>
    <nct_id>NCT01491243</nct_id>
  </id_info>
  <brief_title>N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy</brief_title>
  <acronym>NEW-MOON</acronym>
  <official_title>Neutrophil gElatinase-associated Lipocalin alloWs Intensive treatMent Of cOntrast Induced Nephropathy in Patients With Urgent/Emergency Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who undergo urgent/emergency coronary angiography can not receive any preventive
      treatment of contrast induced nephropathy. We tested the hypothesis that Neutrophil
      gelatinase-associated lipocalin (NGAL), a new biomarker predictive for AKI, allows early and
      effective treatment of contrast induced nephropathy in patients with urgent/emergency
      coronary angiography
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Patients who undergo urgent/emergency coronary angiography can not receive any
      preventive treatment of contrast induced nephropathy.

      An acute kidney injury is generally detected too late to allow effective intervention in
      patients who undergo urgent/emergency coronary angiography.

      Neutrophil gelatinase-associated lipocalin (NGAL) is a new biomarker predictive for AKI
      already shown to be useful for earlier diagnosis of contrast induced nephropathy.

      Purpose The primary objective of this study is to to test the hypothesis that a NGAL-driven
      early intensive strategy can reduce the occurrence of contrast induced nephropathy in
      patients with urgent/emergency coronary angiography
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of contrast induced nephropathy</measure>
    <time_frame>Baseline and 48 hours after angiography</time_frame>
    <description>Absolute increase in serum creatinine equal to or greater than 0.5 mg/dL detected 48 hours after angiography as compared with baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-angiographic changes in renal function parameters</measure>
    <time_frame>Baseline and 48 hours after angiography</time_frame>
    <description>Changes in creatinine levels and estimated glomerular filtration rate at 48-hour evaluation after angiography as compared with baseline values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Intensive treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive high concentration sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h after PCI in case of abnormal NGAL findings</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treament group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive i.v. 1 ml/kg/h saline infusion for 48 h after PCI in case of abnormal NGAL findings</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive treatment with sodium bicarbonate</intervention_name>
    <description>i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings</description>
    <arm_group_label>Intensive treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment with saline infusion</intervention_name>
    <description>i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings</description>
    <arm_group_label>Standard treament group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication to urgent/emergency coronary angiography

          -  Normal renal function (eGFR&gt; 60 ml/min/1.73 m2)

          -  Moderate or high Mehran's risk score for CIN (&gt;11).

          -  Able to understand and willing to sign the informed consent form

        Exclusion Criteria:

        â€¢ Women of child bearing potential patients must demonstrate a negative pregnancy test
        performed within 24 hours before
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francesco Pelliccia, MD</last_name>
    <phone>+393483392006</phone>
    <email>f.pelliccia@mclink.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University La Sapienza</name>
      <address>
        <city>Rome</city>
        <zip>00166</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2011</study_first_submitted>
  <study_first_submitted_qc>December 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <last_update_submitted>March 6, 2013</last_update_submitted>
  <last_update_submitted_qc>March 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Francesco Pelliccia</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>contrast-induced nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

